News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sagent Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2012 Results


2/14/2013 11:18:46 AM

SCHAUMBURG, Ill., Feb. 14, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced financial results for the fourth quarter and fiscal year ended December 31, 2012.
Fourth Quarter 2012 Highlights

• Revenue increased 10% to $53.2 million driven by products launched in the last twelve months;
• Reported gross profit increased 159% to $11.6 million, or 21.8% of net revenue;
• Adjusted gross profit1 increased 152% to $13.1 million, or 24.6% of net revenue;
• Earnings per share increased 100% to essentially breakeven; and
• Seven new products launched, including Calcium Leucovorin, Nafcillin and Ondansetron increasing total for fiscal 2012 to 16 new product launches.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES